My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 500676 | NSE: GSKCONS | Consumer Food | Mid Cap
1. Is a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) is a good quality company.
2. Is undervalued or overvalued?
The key valuation ratios of Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)'s currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | TTM | |||
| ROCE % ⓘ | 28.3% | 32.3% | 33.7% | 34.7% | 42.3% | 29.8% | 27.7% | 22.1% | 21.1% | 25.8% | - | ||
| Value Creation Index ⓘ | 1.1 | 1.4 | 1.5 | 1.6 | 2.1 | 1.7 | 1.5 | 1.0 | 0.9 | 1.3 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 1,922 | 2,306 | 2,765 | 3,187 | 3,895 | 4,308 | 4,136 | 3,991 | 4,317 | 4,782 | 4,984 | ||
| YoY Gr. Rt. % | - | 20% | 19.9% | 15.3% | 22.2% | 10.6% | -4% | -3.5% | 8.2% | 10.8% | - | ||
| Adj EPS ⓘ | 55.4 | 71.2 | 83.8 | 102.9 | 127.4 | 138.9 | 161.7 | 155.5 | 165.3 | 232.3 | 274.8 | ||
| YoY Gr. Rt. % | - | 28.5% | 17.7% | 22.7% | 23.9% | 9% | 16.4% | -3.8% | 6.3% | 40.6% | - | ||
| BVPS (₹) ⓘ | 215.2 | 228.3 | 272.1 | 323.6 | 344.9 | 502.4 | 665.5 | 742.5 | 828.7 | 973.7 | 1,055.4 | ||
| Adj Net Profit ⓘ | 233 | 299 | 352 | 433 | 536 | 584 | 680 | 654 | 695 | 977 | 1,156 | ||
| Cash Flow from Ops. ⓘ | 400 | 326 | 391 | 554 | 516 | 611 | 573 | 603 | 723 | 671 | - | ||
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 10.7% | 4.2% | 5% | 10.8% | ||||||||
| Adj EPS ⓘ | 17.3% | 12.8% | 12.8% | 40.6% | ||||||||
| BVPS ⓘ | 18.3 | 23.1 | 13.5 | 17.5 | ||||||||
| Share Price | 6.3% | 8.1% | -3.4% | -9.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | TTM | ||
| Return on Equity % ⓘ | 28 | 32.1 | 33.5 | 34.5 | 42.2 | 29.8 | 27.7 | 22.1 | 21 | 25.8 | 27.1 | |
| Op. Profit Mgn % ⓘ | 16.3 | 16.4 | 18.2 | 18 | 18 | 17.2 | 20.3 | 21 | 20.5 | 23.9 | 25.4 | |
| Net Profit Mgn % ⓘ | 12.1 | 13 | 12.8 | 13.6 | 13.8 | 13.6 | 16.4 | 16.4 | 16.1 | 20.4 | 23.2 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |
| Working Cap Days ⓘ | 178 | 157 | 170 | 118 | 115 | 223 | 250 | 294 | 324 | 332 | 0 | |
| Cash Conv. Cycle ⓘ | 3 | -12 | -12 | -14 | -14 | -18 | -33 | -43 | -53 | -50 | 0 | |
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Net Profit has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 274.8 | - |
| TTM Sales (₹ Cr.) | 4,984 | - |
| BVPS (₹.) ⓘ | 1,055.4 | - |
| Reserves (₹ Cr.) ⓘ | 4,396 | - |
| P/BV ⓘ | 10.19 | - |
| PE ⓘ | 39.13 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 9696.40 / 10845.75 |
| All Time Low / High (₹) | 93.75 / 11290.00 |
| Market Cap (₹ Cr.) | 45,225 |
| Equity (₹ Cr.) | 42.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 59.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Glaxosmithkline Consumer Healthcare’s (GCH) core business is manufacturing of health drinks under the brand Horlicks. The history of the company goes way back in 1950s when bottled Horlicks was imported from
During 1956-57 a team of Horlicks visited
In the year 1969 Beecham plc acquired
In January 2000 the name was changed to Glaxosmithkline Consumer Healthcare.
It exports products to countries like
GCH has manufacturing plants located at Punjab, Andhra Pradesh, Haryana,
Glaxosmithkline Consumer Healthcare has entered into an agreement with Laclede to purchase its dry mouth brand Biotene for $170 million.
In 2011 GSk has launched Sensodyne in an attempt to enter the Indian tooth paste market. "
Products
Nutritional drinks- Under this it manufactures and markets wide range of health drinks. Besides Horlicks, it has created brands like, Boost, Maltova and Viva. Apart from youth, it also caters to other consumers like mothers with Mother’s Horlicks and Horlicks Lite for diabetic consumers.
OTC Products- It promotes and distributes over the counter drugs like pain relief balm -- Iodex, pain relief tablet and syrup -- Crocin and drug for acidity problems -- Eno.
The company’s nutritional food services division has also developed vending of Boost and Horlicks. Around 500 vending machine have been placed in corporates, schools and hospitals.
Award and Recognition
It manufacturing plants have received various certification for its quality and health and safety systems such as OHSAS 18001, ISO 9001:2000 and ISO 14001:2004 by DNV and SA8000.
The company’s Sonepat factory has won the prestigious “National Energy Conservation Award – 2007†from the President of India in the Food Processing Sector.
Download APP
